The Nordic health registers - An important source when evaluating the safety of antidepressants during pregnancy

Clinical Epidemiology

Volumn 2, Issue 1, 2010, Pages 205-207

  Kieler, Helle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse effect; Antidepressive agents; Multicenter study; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONGENITAL MALFORMATION; DATA ANALYSIS; DEPRESSION; DRUG CHOICE; DRUG SAFETY; HUMAN; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PUBLICATION; REGISTER;

EID: 77957164467     PISSN: None     EISSN: 11791349     Source Type: Book Series    
DOI: 10.2147/CLEP.S10426     Document Type: Article

References (14)

1. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684-2692.
2. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27.
3. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015.
4. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66(5):695-705.
5. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79(4): 301-308.
6. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. Firsttrimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675-2683.
7. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83(1):68-76.
8. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569.
9. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17(6):701-704.
10. Kornum J, Nielesen R, Pedersen L, Mortensen P, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol. 2010(2):29-36
11. O'Keane V, Marsh MS. Depression during pregnancy. BMJ. 2007;334(7601):1003-1005.
12. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507.
13. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600-606.
14. Olsen LR, Mortensen EL, Bech P. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr Scand. 2004;109(2):96-103.